The 4th Annual Engineering Antibodies conference at PEGS Europe presents the latest antibodies to watch, and explores technologies and new approaches to discover, design and engineer novel modalities and new platforms for existing and challenging targets. The conference will also explore new techniques such as deep sequencing, in silico engineering and gene editing to help further the understanding of the sequence and structure-function of the molecules, and close the gap from bench to clinic.
NEW EXPLORATIONS IN ANTIBODY DISCOVERY
OPENING PRESENTATION: Antibodies to Watch in 2020
Janice M. Reichert, PhD, Executive Director, The Antibody Society; Editor-in-Chief, mAbs
KEYNOTE PRESENTATION: Explorations in Antibody Product Discovery
Janine Schuurmann, PhD, Corporate Vice President Research & Innovation, Antibody Research & Technology, Genmab
ANTIBODIES AGAINST DIFFICULT TARGETS
Pipeline Update on GPCR and Ion Channel Antibodies
Catherine Hutchins, PhD, Consultant
Strategies to Isolate and Engineer Functional Antibodies against GPCR and Ion Channel Targets
Trevor Wilkinson, PhD, Associate Director, Antibody Discovery and Protein Engineering, AstraZeneca BioPharmaceuticals Unit
NOVEL MODALITIES AND PLATFORMS
TriTAC: A Tri-Specific T Cell Engaging Platform for the Treatment of Solid Tumors
Bryan D. Lemon, PhD, Senior Director, Protein Science, Harpoon Therapeutics, Inc.
The Making of a Biparatopic Molecule
Fernando Garces, PhD, Senior Scientist, Biologics Optimization, Amgen
The Contorsbody, a Format for Agonism: Design, Structure, Function
Guy Georges, PhD, Expert Scientist, Large Molecule Research, Roche Innovation Center Munich
Targeted Thorium Conjugates (TTCs): A New Modality for the Treatment of Cancer Utilizing Alpha Particle-Based Radiotherapy
Alan Cuthbertson, PhD, Head of Thorium R&D, TCR, Bayer AS
Preclinical Development of ELN/22, A Novel "Super-Neutralising" Solomer™ Specific for Human TNF-Alpha
Obinna Ubah, PhD, Senior Research Scientist, Protein Engineering and Biotechnology, Elasmogen Limited
DEEP sequencing, single cell cloning and novel engineering approaches to antibody discovery & optimisation
Deep Sequencing of Natural Antibody Repertoires for Antibody Discovery and Optimization and Elucidation of Repertoire Properties
Isidro Hotzel, PhD, Senior Scientist, Antibody Engineering, Genentech
Combining Deep Sequencing and High Throughput B Cell Technologies to Maximize Functional Activity Guided Antibodies Discovery and Optimization
Gabriel Wan Cheung, PhD, Senior Director, BioMedicine Design, Pfizer, Inc.
Advancing Therapeutic Protein Development Using a Novel O-Glycan-Based Conjugation Approach
Monika Papworth, PhD, Senior Scientist, Antibody Discovery & Protein Engineering, AstraZeneca
A Platform Approach to Manage Developability and Manufacturability Risks of Biologics Molecules
Sebastian Schlicker, Director, Biologics Business, Genedata
* The program is subject to change without notice, due to unforeseen reason.